Is Moderna Finally Ready To Make A ‘Big Commitment’ On Not-For-Profit COVID-19 Vaccines?
Last Company To Pledge
Some countries want an IP waiver to boost access to vaccines, but industry leaders say this will do nothing to increase output.
You may also be interested in...
Moderna, GSK and Bharat Biotech point to technology transfer, material shortages and manufacturing expertise as factors constraining COVID-19 vaccine supplies, rather than intellectual property rights. Meanwhile, Moderna's CEO forecasts a surplus of these vaccines by 2022.
AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.
Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.